Ramipril Patent Invalid Due To Obviousness: Court

Law360, New York (September 11, 2007, 12:00 AM EDT) -- An appeals court ruled on Tuesday that King Pharmaceutical's patent on its hypertension drug Altace was obvious and thus invalid, overturning a lower court's ruling that generics maker Lupin LTD infringed on the patent.

King, along with German drug maker Aventis Pharma Deuschland GMBH, originally filed a suit against Lupin after Lupin filed an Abbreviated New Drug Application to make a generic version of Altace.

A Virginia district court ruled last year that Lupin's generic drug would have infringed, though it dismissed King and Aventis' claim...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.